Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil
From BioSpace · · 17 min
This plays from the publisher's own server. We do not host a copy.
Not rated yet
Description
A surprising deal from Vertex Pharmaceuticals adds to Big Pharma’s acquisitive streak as Crinetics folds into the cystic fibrosis drugmaker. Meanwhile, IPOs and venture capital raises trend upward, but mostly for derisked companies. Plus, FDA decisions slow only slightly as the hunt for a permanent leader drags on.